Bayer says Lemiretprocel (Opct-001) granted orphan drug designations by FDA and EMA

Bayer said Bluerock Therapeutics’ investigational cell therapy Lemiretprocel (Opct-001) was granted orphan drug designations for primary photoreceptor diseases by the FDA and EMA,